EQL Pharma Dividends and Buybacks
Dividend criteria checks 0/6
EQL Pharma does not have a record of paying a dividend.
Key information
n/a
Dividend yield
-2.0%
Buyback Yield
| Total Shareholder Yield | -2.0% |
| Future Dividend Yield | 0% |
| Dividend Growth | n/a |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Payout ratio | n/a |
Recent dividend and buyback updates
Recent updates
EQL Pharma's (STO:EQL) Weak Earnings May Only Reveal A Part Of The Whole Picture
Nov 15
EQL Pharma AB (publ) (STO:EQL) Shares Slammed 26% But Getting In Cheap Might Be Difficult Regardless
Oct 08Do EQL Pharma's (STO:EQL) Earnings Warrant Your Attention?
Sep 27Capital Allocation Trends At EQL Pharma (STO:EQL) Aren't Ideal
Sep 09EQL Pharma's (STO:EQL) Earnings Are Of Questionable Quality
May 16
Pipeline Launches And Global Expansion Will Drive Future Success
Strategic expansions and acquisitions, including Medilink and non-European market entry, are poised to drive significant revenue and profitability growth.Here's Why EQL Pharma (STO:EQL) Can Manage Its Debt Responsibly
Mar 12EQL Pharma aiming for 19% Revenue Growth in 5 Years
Recurring Cash Flow: EQL’s core generic product delivers near‐“infinite” cash flow, thanks to its essential role in healthcare.The Trend Of High Returns At EQL Pharma (STO:EQL) Has Us Very Interested
Jan 27EQL Pharma AB (publ)'s (STO:EQL) P/E Is Still On The Mark Following 37% Share Price Bounce
Dec 14Should You Be Adding EQL Pharma (STO:EQL) To Your Watchlist Today?
Nov 27Market Participants Recognise EQL Pharma AB (publ)'s (STO:EQL) Earnings Pushing Shares 26% Higher
Oct 29EQL Pharma's (STO:EQL) Shareholders Have More To Worry About Than Only Soft Earnings
Aug 22Here's Why EQL Pharma (STO:EQL) Has A Meaningful Debt Burden
Aug 12EQL Pharma AB (publ)'s (NGM:EQL) P/E Is Still On The Mark Following 30% Share Price Bounce
Jun 13EQL Pharma (NGM:EQL) Is Doing The Right Things To Multiply Its Share Price
May 14EQL Pharma's (NGM:EQL) Weak Earnings May Only Reveal A Part Of The Whole Picture
Feb 21The Trend Of High Returns At EQL Pharma (NGM:EQL) Has Us Very Interested
Jun 28With EPS Growth And More, EQL Pharma (NGM:EQL) Makes An Interesting Case
Apr 28EQL Pharma AB (publ)'s (NGM:EQL) 26% Jump Shows Its Popularity With Investors
Feb 24EQL Pharma (NGM:EQL) Is Achieving High Returns On Its Capital
Dec 19Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if EQL's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if EQL's dividend payments have been increasing.
Dividend Yield vs Market
| EQL Pharma Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (EQL) | n/a |
| Market Bottom 25% (SE) | 1.7% |
| Market Top 25% (SE) | 4.1% |
| Industry Average (Healthcare) | 1.2% |
| Analyst forecast (EQL) (up to 3 years) | 0% |
Notable Dividend: Unable to evaluate EQL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate EQL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate EQL's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as EQL has not reported any payouts.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/17 13:45 |
| End of Day Share Price | 2026/03/17 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
EQL Pharma AB (publ) is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Erik Hultgård | DNB Carnegie Commissioned Research |